ASX - By Stock
|
KZA |
Re:
Excellent interim DIPG data from PNOC
|
|
Rinnekin
|
21 |
6.4K |
2 |
12/11/23 |
12/11/23 |
ASX - By Stock
|
21
|
6.4K
|
2
|
|
ASX - By Stock
|
KZA |
Re:
Excellent interim DIPG data from PNOC
|
|
Rinnekin
|
21 |
6.4K |
6 |
12/11/23 |
12/11/23 |
ASX - By Stock
|
21
|
6.4K
|
6
|
|
ASX - By Stock
|
KZA |
Excellent interim DIPG data from PNOC
|
|
Rinnekin
|
21 |
6.4K |
10 |
12/11/23 |
12/11/23 |
ASX - By Stock
|
21
|
6.4K
|
10
|
|
ASX - By Stock
|
KZA |
Re:
Unravelling glioblastoma’s secrets and harnessing two decades of progress
|
|
Rinnekin
|
9 |
2.5K |
5 |
01/11/23 |
01/11/23 |
ASX - By Stock
|
9
|
2.5K
|
5
|
|
ASX - By Stock
|
KZA |
Re:
Ann: Presentations at upcoming scientific meetings
|
|
Rinnekin
|
4 |
1.9K |
9 |
05/10/23 |
05/10/23 |
ASX - By Stock
|
4
|
1.9K
|
9
|
|
ASX - By Stock
|
KZA |
Re:
Ann: Cleansing Notice
|
|
Rinnekin
|
8 |
2.6K |
2 |
14/07/23 |
14/07/23 |
ASX - By Stock
|
8
|
2.6K
|
2
|
|
ASX - By Stock
|
KZA |
Re:
Ann: Proposed issue of securities - KZA
|
|
Rinnekin
|
10 |
3.0K |
3 |
14/07/23 |
14/07/23 |
ASX - By Stock
|
10
|
3.0K
|
3
|
|
ASX - By Stock
|
KZA |
Re:
Ann: Paxalisib receives Fast Track Designation from US FDA
|
|
Rinnekin
|
42 |
13K |
6 |
13/07/23 |
13/07/23 |
ASX - By Stock
|
42
|
13K
|
6
|
|
ASX - By Stock
|
KZA |
Re:
Ann: Kazia CEO participates in White House Cancer Moonshot Forum
|
|
Rinnekin
|
7 |
2.1K |
9 |
30/05/23 |
30/05/23 |
ASX - By Stock
|
7
|
2.1K
|
9
|
|
ASX - By Stock
|
KZA |
Re:
Ann: GBM Agile Update
|
|
Rinnekin
|
178 |
64K |
5 |
25/05/23 |
25/05/23 |
ASX - By Stock
|
178
|
64K
|
5
|
|
ASX - By Stock
|
KZA |
Re:
DIPG Panel Discussion
|
|
Rinnekin
|
103 |
39K |
2 |
21/05/23 |
21/05/23 |
ASX - By Stock
|
103
|
39K
|
2
|
|
ASX - By Stock
|
KZA |
Re:
DIPG Panel Discussion
|
|
Rinnekin
|
103 |
39K |
6 |
20/05/23 |
20/05/23 |
ASX - By Stock
|
103
|
39K
|
6
|
|
ASX - By Stock
|
KZA |
Re:
DIPG Panel Discussion
|
|
Rinnekin
|
103 |
39K |
11 |
18/05/23 |
18/05/23 |
ASX - By Stock
|
103
|
39K
|
11
|
|
ASX - By Stock
|
KZA |
Re:
Ann: GBM Agile Update
|
|
Rinnekin
|
178 |
64K |
7 |
10/05/23 |
10/05/23 |
ASX - By Stock
|
178
|
64K
|
7
|
|
ASX - By Stock
|
KZA |
Re:
Ann: Quarterly Activities/Appendix 4C Cash Flow Report
|
|
Rinnekin
|
6 |
2.0K |
14 |
29/04/23 |
29/04/23 |
ASX - By Stock
|
6
|
2.0K
|
14
|
|
ASX - By Stock
|
KZA |
Re:
Ann: Kazia presents new data at AACR Annual Meeting
|
|
Rinnekin
|
36 |
14K |
9 |
27/04/23 |
27/04/23 |
ASX - By Stock
|
36
|
14K
|
9
|
|
ASX - By Stock
|
KZA |
Re:
DIPG Panel Discussion
|
|
Rinnekin
|
103 |
39K |
13 |
27/04/23 |
27/04/23 |
ASX - By Stock
|
103
|
39K
|
13
|
|
ASX - By Stock
|
KZA |
Re:
DIPG Panel Discussion
|
|
Rinnekin
|
103 |
39K |
9 |
26/04/23 |
26/04/23 |
ASX - By Stock
|
103
|
39K
|
9
|
|
ASX - By Stock
|
KZA |
Re:
DIPG Panel Discussion
|
|
Rinnekin
|
103 |
39K |
12 |
26/04/23 |
26/04/23 |
ASX - By Stock
|
103
|
39K
|
12
|
|
ASX - By Stock
|
KZA |
Re:
Ann: Kazia presents new data at AACR Annual Meeting
|
|
Rinnekin
|
36 |
14K |
0 |
24/04/23 |
24/04/23 |
ASX - By Stock
|
36
|
14K
|
0
|
|
ASX - By Stock
|
KZA |
Re:
Ann: Kazia presents new data at AACR Annual Meeting
|
|
Rinnekin
|
36 |
14K |
5 |
21/04/23 |
21/04/23 |
ASX - By Stock
|
36
|
14K
|
5
|
|
ASX - By Stock
|
KZA |
Re:
Ann: Kazia presents new data at AACR Annual Meeting
|
|
Rinnekin
|
36 |
14K |
3 |
04/04/23 |
04/04/23 |
ASX - By Stock
|
36
|
14K
|
3
|
|
ASX - By Stock
|
KZA |
Re:
Ann: Kazia presents new data at AACR Annual Meeting
|
|
Rinnekin
|
36 |
14K |
7 |
04/04/23 |
04/04/23 |
ASX - By Stock
|
36
|
14K
|
7
|
|
ASX - By Stock
|
KZA |
Re:
DIPG Panel Discussion
|
|
Rinnekin
|
103 |
39K |
9 |
13/02/23 |
13/02/23 |
ASX - By Stock
|
103
|
39K
|
9
|
|
ASX - By Stock
|
KZA |
Re:
DIPG Panel Discussion
|
|
Rinnekin
|
103 |
39K |
12 |
09/02/23 |
09/02/23 |
ASX - By Stock
|
103
|
39K
|
12
|
|
ASX - By Stock
|
KZA |
Paxalisib in DIPG - Phase 1 completed
|
|
Rinnekin
|
0 |
460 |
7 |
19/01/23 |
19/01/23 |
ASX - By Stock
|
0
|
460
|
7
|
|
ASX - By Stock
|
KZA |
Re:
Ann: Kazia raises $4.5m and launches share purchase plan
|
|
Rinnekin
|
32 |
11K |
6 |
16/01/23 |
16/01/23 |
ASX - By Stock
|
32
|
11K
|
6
|
|
ASX - By Stock
|
KZA |
Re:
Ann: Trading Halt
|
|
Rinnekin
|
22 |
8.3K |
1 |
12/01/23 |
12/01/23 |
ASX - By Stock
|
22
|
8.3K
|
1
|
|
ASX - By Stock
|
KZA |
Re:
Ann: Trading Halt
|
|
Rinnekin
|
22 |
8.3K |
5 |
12/01/23 |
12/01/23 |
ASX - By Stock
|
22
|
8.3K
|
5
|
|
ASX - By Stock
|
KZA |
Re:
Ann: Trading Halt
|
|
Rinnekin
|
22 |
8.3K |
7 |
12/01/23 |
12/01/23 |
ASX - By Stock
|
22
|
8.3K
|
7
|
|
ASX - By Stock
|
KZA |
Re:
Is Labman on the money?
|
|
Rinnekin
|
8 |
4.4K |
4 |
01/01/23 |
01/01/23 |
ASX - By Stock
|
8
|
4.4K
|
4
|
|
ASX - By Stock
|
KZA |
Re:
Ann: Interim data from MSKCC study
|
|
Rinnekin
|
47 |
21K |
4 |
19/12/22 |
19/12/22 |
ASX - By Stock
|
47
|
21K
|
4
|
|
ASX - By Stock
|
KZA |
Re:
Is 15.7 months mOS good enough for GBM? Can it be statistically significant?
|
|
Rinnekin
|
3 |
1.5K |
10 |
15/08/22 |
15/08/22 |
ASX - By Stock
|
3
|
1.5K
|
10
|
|
ASX - By Stock
|
KZA |
Re:
KZA Media Thread
|
|
Rinnekin
|
2.0K |
622K |
4 |
13/06/22 |
13/06/22 |
ASX - By Stock
|
2.0K
|
622K
|
4
|
|
ASX - By Stock
|
KZA |
Re:
News: KZA Kazia Says Phase II Study Of Paxalisib In Brain Metastases Advances To Expansion Stage In...
|
|
Rinnekin
|
17 |
5.2K |
11 |
07/06/22 |
07/06/22 |
ASX - By Stock
|
17
|
5.2K
|
11
|
|
ASX - By Stock
|
KZA |
Edison: Report on paxalisib in childhood cancers
|
|
Rinnekin
|
0 |
390 |
12 |
24/05/22 |
24/05/22 |
ASX - By Stock
|
0
|
390
|
12
|
|
ASX - By Stock
|
KZA |
DIPG Panel Discussion
|
|
Rinnekin
|
103 |
39K |
7 |
20/05/22 |
20/05/22 |
ASX - By Stock
|
103
|
39K
|
7
|
|
ASX - By Stock
|
KZA |
Re:
The End-of-the-Road for Immunotherapies in GBM CheckMate 498
|
|
Rinnekin
|
13 |
4.0K |
5 |
06/05/22 |
06/05/22 |
ASX - By Stock
|
13
|
4.0K
|
5
|
|
ASX - By Stock
|
KZA |
Latest interview
|
|
Rinnekin
|
71 |
22K |
14 |
03/05/22 |
03/05/22 |
ASX - By Stock
|
71
|
22K
|
14
|
|
ASX - By Stock
|
KZA |
Re:
Ann: Quarterly Activities/Appendix 4C Cash Flow Report
|
|
Rinnekin
|
57 |
16K |
6 |
29/04/22 |
29/04/22 |
ASX - By Stock
|
57
|
16K
|
6
|
|
ASX - By Stock
|
KZA |
Re:
Ann: Kazia releases final data from P2 paxalisib trial
|
|
Rinnekin
|
107 |
33K |
3 |
05/04/22 |
05/04/22 |
ASX - By Stock
|
107
|
33K
|
3
|
|
ASX - By Stock
|
KZA |
Re:
Dr. Matt Dun - Treatment Strategies for Kids battling DIPG/DMG
|
|
Rinnekin
|
25 |
8.1K |
18 |
06/02/22 |
06/02/22 |
ASX - By Stock
|
25
|
8.1K
|
18
|
|
ASX - By Stock
|
KZA |
Re:
Kazia Share Price
|
|
Rinnekin
|
791 |
219K |
10 |
14/01/22 |
14/01/22 |
ASX - By Stock
|
791
|
219K
|
10
|
|
ASX - By Stock
|
KZA |
Re:
Kazia Share Price
|
|
Rinnekin
|
791 |
219K |
4 |
24/12/21 |
24/12/21 |
ASX - By Stock
|
791
|
219K
|
4
|
|
ASX - By Stock
|
KZA |
Re:
Kazia Share Price
|
|
Rinnekin
|
791 |
219K |
13 |
24/12/21 |
24/12/21 |
ASX - By Stock
|
791
|
219K
|
13
|
|
ASX - By Stock
|
KZA |
Re:
Data
|
|
Rinnekin
|
14 |
4.4K |
8 |
22/12/21 |
22/12/21 |
ASX - By Stock
|
14
|
4.4K
|
8
|
|
ASX - By Stock
|
KZA |
Re:
KZA Chart
|
|
Rinnekin
|
559 |
156K |
15 |
11/12/21 |
11/12/21 |
ASX - By Stock
|
559
|
156K
|
15
|
|
ASX - By Stock
|
KZA |
Re:
How does GBM AGILE work?
|
|
Rinnekin
|
73 |
24K |
15 |
09/12/21 |
09/12/21 |
ASX - By Stock
|
73
|
24K
|
15
|
|
ASX - By Stock
|
KZA |
Re:
Ann: Kazia releases final data from P2 paxalisib trial
|
|
Rinnekin
|
107 |
33K |
5 |
06/12/21 |
06/12/21 |
ASX - By Stock
|
107
|
33K
|
5
|
|
ASX - By Stock
|
KZA |
Re:
Ann: Kazia releases final data from P2 paxalisib trial
|
|
Rinnekin
|
107 |
33K |
6 |
06/12/21 |
06/12/21 |
ASX - By Stock
|
107
|
33K
|
6
|
|